| 2022-08-12 8:56:20 am |
PhaseBio Pharmaceuticals (PHAS) Investor Presentation - Slideshow |
SeekingAlpha |
| Aug-12-22 09:45AM |
PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates |
Zacks |
| Aug-12-22 08:30AM |
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights |
Business Wire |
| Jul-09-22 09:00AM |
Strong week for PhaseBio Pharmaceuticals (NASDAQ:PHAS) shareholders doesn't alleviate pain of three-year loss |
Simply Wall St. |
| May-16-22 07:15AM |
PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates |
Zacks |
| May-16-22 06:00AM |
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights |
Business Wire |
| May-16-22 06:00AM |
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab |
Business Wire |
| Apr-18-22 03:40PM |
Needham Estimates PhaseBio Pharma's Bentracimab Market Opportunity Of Up To $1.5B |
Benzinga |
| Apr-08-22 12:15PM |
Lab Notes: Venatorx closes Series C financing; Ocugen takes 'critical' step in clinical trial |
American City Business Journals |
| Apr-07-22 04:00PM |
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference |
Business Wire |
| Apr-04-22 08:00AM |
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab |
Business Wire |
| Mar-24-22 04:00PM |
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights |
Business Wire |
| Mar-08-22 08:00AM |
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update |
Business Wire |
| Feb-24-22 04:00PM |
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference |
Business Wire |
| Feb-10-22 08:00AM |
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session |
Business Wire |
| Dec-21-21 12:43PM |
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset |
Benzinga |
| Dec-21-21 08:00AM |
PhaseBio Provides Pemziviptadil (PB1046) Program Update |
Business Wire |
| Dec-13-21 11:00AM |
PhaseBio Pharmaceuticals (NASDAQ:PHAS) adds US$20m to market cap in the past 7 days, though investors from a year ago are still down 45% |
Simply Wall St. |
| Dec-01-21 05:01PM |
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence |
Business Wire |
| Nov-18-21 04:01PM |
PhaseBio Names Jonathan Birchall as Chief Commercial Officer |
Business Wire |
| Nov-16-21 11:50AM |
PhaseBio (PHAS) Dips on Mixed Data From Antiplatelet Drug Study |
Zacks |
| Nov-15-21 02:32PM |
PhaseBio Says Antiplatelet Candidate Achieved Primary Reversal Endpoint In Late-Stage Study |
Benzinga |
| Nov-15-21 01:24PM |
PhaseBio shares fall despite positive late-stage study results for lead drug candidate |
American City Business Journals |
| Nov-15-21 11:31AM |
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding |
Business Wire |
| Nov-10-21 05:15PM |
PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates |
Zacks |
| Nov-10-21 04:00PM |
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights |
Business Wire |
| Nov-10-21 08:01AM |
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting |
Business Wire |
| Nov-03-21 10:51AM |
PerkinElmer Q3 Earnings, FY21 Guidance Beat Wall Street Expectations |
Benzinga |
| Nov-03-21 10:10AM |
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study |
Benzinga |
| Nov-03-21 08:00AM |
PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab |
Business Wire |
| Oct-07-21 07:57AM |
Do Options Traders Know Something About PhaseBio Pharmaceuticals (PHAS) Stock We Don't? |
Zacks |
| Oct-06-21 08:00AM |
PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial Accepted for Late Breaking Science Presentation at the American Heart Association Scientific Sessions 2021 |
Business Wire |
| Sep-15-21 08:00AM |
PhaseBio Appoints William D. Humphries to Board of Directors |
Business Wire |
| Sep-14-21 10:37AM |
Is PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Popular Amongst Institutions? |
Simply Wall St. |
| Sep-07-21 08:30AM |
Absci Reports Second Quarter 2021 Financial and Operating Results |
GlobeNewswire |
| Aug-31-21 04:00PM |
PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference |
Business Wire |
| Aug-12-21 08:30AM |
PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights |
Business Wire |
| Aug-12-21 08:00AM |
PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor |
Business Wire |
| Aug-10-21 08:00AM |
PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab |
Business Wire |
| Aug-03-21 09:20AM |
New Strong Sell Stocks for August 3rd |
Zacks |
| Jun-30-21 04:00PM |
PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15 |
Business Wire |
| Jun-17-21 08:35AM |
PhaseBio Stock Jumps On Bentracimab Commercialization Pact In Europe |
Benzinga |
| Jun-17-21 08:00AM |
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab |
Business Wire |
| Jun-15-21 05:31AM |
Is PhaseBio Pharmaceuticals (NASDAQ:PHAS) Using Too Much Debt? |
Simply Wall St. |
| May-20-21 04:30PM |
PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference |
Business Wire |
| May-17-21 04:30PM |
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session |
Business Wire |
| May-13-21 05:25PM |
PHASEBIO PHARMA (PHAS) Reports Q1 Loss, Lags Revenue Estimates |
Zacks |
| May-13-21 04:00PM |
PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights |
Business Wire |
| May-04-21 03:00PM |
Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for |
Zacks |
| Apr-07-21 04:05PM |
PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference |
Business Wire |
| Mar-22-21 04:05PM |
PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares |
Business Wire |
| Mar-17-21 10:10PM |
PhaseBio Announces Pricing of Public Offering of Common Stock |
Business Wire |
| Mar-17-21 05:02PM |
PhaseBio Announces Proposed Public Offering of Common Stock |
Business Wire |
| Mar-15-21 08:00AM |
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights |
Business Wire |
| Mar-11-21 08:00AM |
PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab |
Business Wire |
| Feb-26-21 04:02AM |
Reflecting on PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Share Price Returns Over The Last Year |
Simply Wall St. |
| Feb-24-21 04:15PM |
PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021 |
Business Wire |
| Jan-28-21 08:00AM |
PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor |
Business Wire |
| Jan-27-21 04:05PM |
PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress |
Business Wire |
| Jan-11-21 08:54AM |
Is the Options Market Predicting a Spike in PhaseBio (PHAS) Stock? |
Zacks |
| Nov-30-20 09:16PM |
Is PhaseBio Pharmaceuticals (PHAS) A Good Stock To Buy Now? |
Insider Monkey |
| Nov-16-20 06:22AM |
Earnings Update: PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Just Reported And Analysts Are Trimming Their Forecasts |
Simply Wall St. |
| Nov-12-20 04:05PM |
PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results |
Business Wire |
| Nov-11-20 05:33PM |
PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th |
Business Wire |
| Oct-26-20 04:02AM |
PhaseBio Plunges 10% As Covid-19 Trial Called Off; Street Stays Bullish |
SmarterAnalyst |
| Oct-23-20 08:00AM |
PhaseBio Provides Pemziviptadil (PB1046) Program Update |
Business Wire |
| Oct-12-20 01:00PM |
What Kind Of Investors Own Most Of PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS)? |
Simply Wall St. |
| Oct-06-20 08:00AM |
PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor |
Business Wire |
| Sep-09-20 04:05PM |
PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference |
Business Wire |
| Aug-11-20 05:25PM |
PHASEBIO PHARMA (PHAS) Reports Q2 Loss, Lags Revenue Estimates |
Zacks |
| Aug-11-20 04:01PM |
PhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial Results |
Business Wire |
| Aug-04-20 12:30PM |
Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for |
Zacks |
| Aug-03-20 04:01PM |
PhaseBio to Present at the William Blair Biotech Focus Conference 2020 |
Business Wire |
| Jul-20-20 09:58AM |
PhaseBio Initiates Phase II Study for Coronavirus Patients |
Zacks |
| Jul-17-20 07:41AM |
The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient |
Benzinga |
| Jul-16-20 04:05PM |
PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients |
Business Wire |
| Jul-12-20 09:32AM |
What You Need To Know About The PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Analyst Downgrade Today |
Simply Wall St. |
| Jul-06-20 07:47PM |
3 Coronavirus Penny Stocks With Triple-Digit Upside Potential |
TipRanks |
| Jun-15-20 08:51PM |
Hedge Funds Are Selling PhaseBio Pharmaceuticals, Inc. (PHAS) |
Insider Monkey |
| Jun-03-20 09:56AM |
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More |
Zacks |
| May-28-20 12:53PM |
PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment |
Zacks |
| May-28-20 10:40AM |
P/E Ratio Insights for PhaseBio Pharmaceuticals |
Benzinga |
| May-28-20 10:00AM |
PhaseBio Cleared by FDA for Trial of Virus Treatment |
TheStreet.com |
| May-28-20 08:24AM |
The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer |
Benzinga |
| May-28-20 01:32AM |
PhaseBio Explodes 82% After-Hours On FDA Nod For Covid-19 Clinical Trial |
SmarterAnalyst |
| May-27-20 04:01PM |
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients |
Business Wire |
| May-12-20 05:15PM |
PHASEBIO PHARMA (PHAS) Reports Q1 Loss, Lags Revenue Estimates |
Zacks |
| May-12-20 04:01PM |
PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights |
Business Wire |
| May-07-20 12:30PM |
Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for |
Zacks |
| Apr-23-20 11:42AM |
PhaseBio Pharmaceuticals, Inc. (PHAS) Shares March Higher, Can It Continue? |
Zacks |
| Apr-14-20 10:18AM |
Easy Come, Easy Go: How PhaseBio Pharmaceuticals (NASDAQ:PHAS) Shareholders Got Unlucky And Saw 74% Of Their Cash Evaporate |
Simply Wall St. |
| Mar-30-20 08:01AM |
PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights |
GlobeNewswire |
| Mar-17-20 12:30PM |
Analysts Estimate PHASEBIO PHARMA (PHAS) to Report a Decline in Earnings: What to Look Out for |
Zacks |
| Feb-26-20 04:01PM |
PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference |
GlobeNewswire |
| Feb-13-20 04:01PM |
PhaseBio Appoints Alex C. Sapir to Board of Directors |
GlobeNewswire |
| Feb-11-20 08:00AM |
PhaseBio Announces European Regulatory Update for PB2452 |
GlobeNewswire |
| Feb-06-20 10:40AM |
Wall Street Pros: These 3 Stocks Can Double Next Year |
TipRanks |
| Feb-05-20 07:43AM |
The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data |
Benzinga |
| Feb-04-20 04:01PM |
PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress |
GlobeNewswire |
| Jan-15-20 09:13AM |
Rock star Growth Puts PhaseBio Pharmaceuticals (NASDAQ:PHAS) In A Position To Use Debt |
Simply Wall St. |
| Jan-14-20 07:55AM |
The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug |
Benzinga |